A first-in-man clinical evaluation of sirolimus and ascorbic acid-eluting stent systems: A multicenter, subject-blinded, randomized study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, Young-Hyo | - |
dc.contributor.author | Youn, Ji Hyun | - |
dc.contributor.author | Hong, Soon-Jun | - |
dc.contributor.author | Ahn, Tae-Hoon | - |
dc.contributor.author | Yoon, Junghan | - |
dc.contributor.author | Park, Jun-Kyu | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2022-07-06T11:06:12Z | - |
dc.date.available | 2022-07-06T11:06:12Z | - |
dc.date.created | 2021-12-08 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/140179 | - |
dc.description.abstract | Background and Objectives: This clinical trial was conducted to evaluate the safety and efficacy of D+Storm™ drug-eluting stent (DES) and BioMatrix Flex™ DES. Methods: This study was a multicenter, subject-single-blind, randomized, and confirmed comparative clinical trial. According to the inclusion criteria, those diagnosed with stable angina, unstable angina, silent ischemia, or non-ST-segment myocardial infarction were selected among patients with coronary artery stenosis as subjects. Among the subjects with 50% stenosis on coronary angiography, the experiment was performed on those who had a lesion with reference vessel 2.5–4.0 mm in diameter and ≤40 mm in length. The primary endpoint was an in-segment late loss and the secondary endpoints were in-stent late lumen loss, stent malapposition, the incidence of mortality, myocardial infarction, reoperation, and stent thrombosis at 36 weeks. Results: 57 patients in the D+Storm™ DES group and 55 patients in the BioMatrix Flex™ DES group were enrolled in the study. Fifty-seven patients in the D+Storm™ DES group and Fifty-five patients in the BioMatrix Flex™ DES group were enrolled in the study. An average of in-segment late lumen loss was 0.08±0.13 mm in the D+Storm™ DES group and 0.14±0.32 mm in the BioMatrix Flex™ DES group with no significant difference between the 2 groups (p=0.879). In addition, there was no significant difference in adverse events between D+Storm™ DES and BioMatrix Flex™ DES. Conclusions: This study demonstrated the clinical effectiveness and safety of D+Storm™ DES implantation in patients with coronary artery disease over a 36-week follow-up period. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Circulation | - |
dc.title | A first-in-man clinical evaluation of sirolimus and ascorbic acid-eluting stent systems: A multicenter, subject-blinded, randomized study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Young-Hyo | - |
dc.identifier.doi | 10.4070/KCJ.2021.0161 | - |
dc.identifier.scopusid | 2-s2.0-85117920540 | - |
dc.identifier.wosid | 000729805700005 | - |
dc.identifier.bibliographicCitation | Korean Circulation Journal, v.51, no.12, pp.1001 - 1014 | - |
dc.relation.isPartOf | Korean Circulation Journal | - |
dc.citation.title | Korean Circulation Journal | - |
dc.citation.volume | 51 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1001 | - |
dc.citation.endPage | 1014 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002781568 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | RESTENOSIS | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | GENERATION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordAuthor | Absorbable implants | - |
dc.subject.keywordAuthor | Ascorbic acid | - |
dc.subject.keywordAuthor | Coronary artery disease | - |
dc.subject.keywordAuthor | Drug-eluting stents | - |
dc.subject.keywordAuthor | Sirolimus | - |
dc.identifier.url | https://e-kcj.org/DOIx.php?id=10.4070/kcj.2021.0161 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.